Long-term pioglitazone effect on triple transgenic model of Alzheimer's disease (3xTg-AD): hippocampus
Summary:
Analysis of hippocampus from 10 month-old, triple-transgenic AD females treated with the thiazolidinedione pioglitazone (PIO) for 14 weeks. TZDs exert cognitive benefits early in the AD process. Results provide insight into molecular mechanisms underlying the neuroprotective role of PIO in AD.
Searcy JL, Phelps JT, Pancani T, Kadish I et al. Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. J Alzheimers Dis 2012;30(4):943-61. PMID: 22495349
